PL2374819T3 - Antibodies to MASP-2 - Google Patents

Antibodies to MASP-2

Info

Publication number
PL2374819T3
PL2374819T3 PL11172040T PL11172040T PL2374819T3 PL 2374819 T3 PL2374819 T3 PL 2374819T3 PL 11172040 T PL11172040 T PL 11172040T PL 11172040 T PL11172040 T PL 11172040T PL 2374819 T3 PL2374819 T3 PL 2374819T3
Authority
PL
Poland
Prior art keywords
masp
antibodies
Prior art date
Application number
PL11172040T
Other languages
Polish (pl)
Inventor
Flemming Larsen
Ulla Wahlers
Original Assignee
Helion Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helion Biotech Aps filed Critical Helion Biotech Aps
Publication of PL2374819T3 publication Critical patent/PL2374819T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
PL11172040T 2003-05-12 2004-05-12 Antibodies to MASP-2 PL2374819T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300716 2003-05-12

Publications (1)

Publication Number Publication Date
PL2374819T3 true PL2374819T3 (en) 2017-09-29

Family

ID=33483731

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11172040T PL2374819T3 (en) 2003-05-12 2004-05-12 Antibodies to MASP-2
PL04732276T PL1625166T3 (en) 2003-05-12 2004-05-12 Antibodies to masp-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04732276T PL1625166T3 (en) 2003-05-12 2004-05-12 Antibodies to masp-2

Country Status (11)

Country Link
US (8) US9096676B2 (en)
EP (2) EP1625166B1 (en)
CN (1) CN1798769A (en)
CY (2) CY1116506T1 (en)
DK (2) DK2374819T3 (en)
ES (2) ES2629344T3 (en)
HU (2) HUE034760T2 (en)
PL (2) PL2374819T3 (en)
PT (2) PT2374819T (en)
SI (2) SI2374819T1 (en)
WO (1) WO2004106384A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Antibodies to MASP-2
AU2013201565B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
DK2446900T3 (en) * 2004-06-10 2017-07-10 Omeros Corp Methods for treating conditions associated with MASP-2-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8652477B2 (en) * 2009-10-16 2014-02-18 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8859209B2 (en) 2006-01-12 2014-10-14 Carviar Aps Reimmunization and antibody design
WO2007095154A2 (en) * 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
WO2007124755A1 (en) 2006-05-02 2007-11-08 The Antibody Project Aps Method for immunizing an avian species
AR071698A1 (en) * 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg ANTIBODIES AGAINST THE RECEIVER OF ADVANCED GLICOSILATION (RAGE) FINAL PRODUCTS AND USES OF THE SAME
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK3287142T3 (en) 2011-04-08 2021-11-01 Univ Leicester METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENTATION ACTIVATION
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CN103614341B (en) * 2013-09-02 2016-07-13 杨旸 Anti-mannan-binding lectin monoclonal antibodies and kit
NZ719476A (en) * 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
CN111696895A (en) * 2014-11-25 2020-09-22 应用材料公司 Substrate processing system, apparatus and method with substrate carrier and purge chamber environmental control
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
EP3436072A4 (en) 2016-03-31 2019-11-06 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
JOP20190068A1 (en) * 2016-10-13 2019-04-01 Omeros Corp Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
TW202402809A (en) 2017-08-15 2024-01-16 美商歐米諾斯公司 Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
WO2019246367A1 (en) * 2018-06-22 2019-12-26 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
PE20220431A1 (en) 2019-05-07 2022-03-29 Bayer Ag MASP INHIBITOR COMPOUNDS AND THEIR USES
WO2022096394A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN115215937B (en) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
KR20240038716A (en) * 2021-06-30 2024-03-25 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 Novel anti-MASP-2 antibodies
CN116615544A (en) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 Antibodies specifically recognizing MASP2 and uses thereof
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US558767A (en) 1896-04-21 Oyster-dredger
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPH0662679B2 (en) * 1985-06-21 1994-08-17 新田ゼラチン株式会社 Tissue-friendly collagen and its manufacturing method
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
AR243935A1 (en) 1987-12-15 1993-09-30 Gene Shears Pty Ltd Ribozymes
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) * 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (en) * 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (en) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
DK0590058T3 (en) * 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (en) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd Monoclonal antibody to human masp
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) * 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (en) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solution for irrigation and method for inhibiting pain, inflammation and sparse
US5739119A (en) * 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6008017A (en) * 1997-01-02 1999-12-28 Smithkline Beecham Corporation Human cardiac/brain tolloid-like protein
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5955309A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation Polynucleotide encoding G-protein coupled receptor (H7TBA62)
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
CA2347734A1 (en) 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) * 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
US20020015957A1 (en) * 2000-04-29 2002-02-07 Hageman Gregory S. Diagnostics and therapeutics for macular degeneration-related disorders
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
NZ515717A (en) * 1999-05-14 2004-01-30 Jens Christian Jensenius Process to produce recombinant human mannan-binding lectin and its use in treatments of disorders of the immune system
DE60039301D1 (en) 1999-07-21 2008-08-07 Omeros Corp RINSE SOLUTIONS AND METHODS FOR PAIN-INHIBITING, INFLAMMATION-INHIBITING AND INHIBITION OF CARTILAGE REMOVAL
CA2381396A1 (en) 1999-08-11 2001-02-15 Curagen Corporation Polynucleotides and polypeptides encoded thereby
JP2003507338A (en) 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド Lectin complement pathway (LCP) inhibitors and uses thereof
US20030186419A1 (en) * 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) * 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) * 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN1449440A (en) * 2000-07-13 2003-10-15 詹斯·C·詹斯尼厄斯 Masp-2, a complement-fixing enzyme, and uses for it
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
JP2004536138A (en) 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to improve recognition
WO2003061765A1 (en) 2002-01-22 2003-07-31 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp Compositions and methods for systemic inhibition of cartilage degradation
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
AU2003283217A1 (en) 2002-12-03 2004-06-23 Aarhus Amt Method for determing predisposition to manifestation of immune system related diseases
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CN101897969B (en) 2003-02-21 2014-04-02 健泰科生物技术公司 Use of complement inhibitors in preparing medicines for preventing or treating tissure damage
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Antibodies to MASP-2
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005024013A1 (en) 2003-09-05 2005-03-17 Natimmune A/S Masp-2 crystal structure and uses thereof
SG10201606980VA (en) * 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
DK2446900T3 (en) 2004-06-10 2017-07-10 Omeros Corp Methods for treating conditions associated with MASP-2-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
NZ599144A (en) * 2006-09-08 2013-10-25 Abbott Lab Interleukin -13 binding proteins

Also Published As

Publication number Publication date
EP1625166A1 (en) 2006-02-15
ES2629344T3 (en) 2017-08-08
CN1798769A (en) 2006-07-05
US20200199252A1 (en) 2020-06-25
HUE034760T2 (en) 2018-02-28
ES2541134T3 (en) 2015-07-16
SI2374819T1 (en) 2017-09-29
US10189909B2 (en) 2019-01-29
US11008405B2 (en) 2021-05-18
US11225526B2 (en) 2022-01-18
SI1625166T1 (en) 2015-08-31
US20230058435A1 (en) 2023-02-23
HUE024996T2 (en) 2016-01-28
US20210221913A1 (en) 2021-07-22
US20210261688A1 (en) 2021-08-26
US20200216566A1 (en) 2020-07-09
US20160096897A1 (en) 2016-04-07
WO2004106384A1 (en) 2004-12-09
US11008404B2 (en) 2021-05-18
EP1625166B1 (en) 2015-04-08
US20070009528A1 (en) 2007-01-11
US9096676B2 (en) 2015-08-04
DK1625166T3 (en) 2015-07-13
EP2374819A1 (en) 2011-10-12
CY1119106T1 (en) 2018-02-14
PT2374819T (en) 2017-07-04
DK2374819T3 (en) 2017-06-06
EP2374819B1 (en) 2017-03-22
PT1625166E (en) 2015-08-20
US20190144564A1 (en) 2019-05-16
CY1116506T1 (en) 2017-03-15
PL1625166T3 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
SI1625166T1 (en) Antibodies to masp-2
EP1616881A4 (en) Anti-mpl antibodies
IL175608A0 (en) Antibodies
PT1599504E (en) Modified antibody
IL175523A0 (en) Interleukin-10 antibodies
EP1648512A4 (en) Anti-cd19 antibodies
HK1087131A1 (en) Anti-igfr1 antibody therapeutic combinations
IL173557A0 (en) Variable antibodies
GB0305702D0 (en) Bispecific antibodies
IL181575A0 (en) Anti-ox40l antibodies
EP1670825A4 (en) Antibodies to m-csf
IL228033A0 (en) Antibodies
SI1587542T1 (en) Use of anti-cd100 antibodies
GB0420466D0 (en) Anti-glucan antibodies
AU2003218456A8 (en) Antibodies that specifically bind to gmad
IL172511A0 (en) Specific human antibodies
EP1598368A4 (en) Anti-pci neutralizing antibodies
ZA200701952B (en) Anti-OX40L antibodies
GB0306618D0 (en) Antibody
HK1209139A1 (en) Modified antibody
GB0317974D0 (en) Novel antibodies
GB0329711D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0319118D0 (en) Variable antibodies
GB0319345D0 (en) Variable antibodies